Article Text

Download PDFPDF

936 Post neoadjuvant chemotherapy tissues enriched in a distinct CD27IgDCD21-CXCR5- atypical double negative (DN)2 B cells, with potential role in purinergic signalling in early breast cancers
  1. Esme Carpenter1,
  2. Paul Buckley1,
  3. Thanussuyah Alaguthurai1,
  4. Rosalind Graham1,
  5. Helen Kakkassery1,
  6. Gheed Alhity1,
  7. Farhana Hossain2,
  8. Sadiyah Mukhtar2 and
  9. Sheeba Irshad1
  1. 1King’s College London, London, UK
  2. 2Guy’s and St Thomas’ NHS Foundation Trust, London, UK
  • Journal for ImmunoTherapy of Cancer (JITC) preprint. The copyright holder for this preprint are the authors/funders, who have granted JITC permission to display the preprint. All rights reserved. No reuse allowed without permission.


Background B cells exhibit diverse phenotypes and function and the complex interplay between different B cell subsets in the context of chemotherapy treated breast cancers remains unclear. Here, we investigate the dynamic changes in the B cell immune landscape before and after neoadjuvant chemotherapy (NACT) treatment across different breast cancer subtypes.

Methods Treatment naïve, mid-treatment and post-NACT breast tumour, matched lymph node, blood and serum samples were profiled for B cell subsets and cytokines by flow cytometry, cytometry by time-of-flight (CyTOF) and Luminex technologies. Ex vivo autologous tumour organoid and immune cells cocultures to functionally assess the B-cell interactions across breast cancer subtypes were performed. Multiplex spatial analysis method was used to explore the dynamics of double negative B cell cellular crosstalk within the tumour and axillary lymph nodes. The results are being associated with treatment outcomes. Expression and activity of purinergic ectoenzymes within B cell subsets were also assessed by flow cytometry and high-performance liquid chromatography. Current work focusses on how these findings may relate to immunotherapy response, a new paradigm shift in the treatment of triple negative breast cancer patients.

Results We observed a significant expansion in the CD20+CD27IgDcells, also termed as double-negative (DN) B cells, within the TME of treatment naïve and post-neoadjuvant residual tumours compared to the periphery. Specifically, DN1 (CD20+ CD27IgD CD21+CXCR5+) cells represented the majority of DN B cells within the treatment naïve TME and in circulation. However, NACT promotes an expansion of the DN2 (CD20+CD27IgDCD21-CXCR5-) subset as well as a relatively uncharacterised DN3 (CD19+IgDCD27CXCR5CD11c) cell population. Analyses on how these changes (especially with DN2 cells) relate to treatment response are ongoing. Among circulating B, T and NK cells, B cells showed the highest CD73 and CD39 surface expression at baseline, but their expression significantly dropped following NACT especially within the DN2 B cell subset. These ecto-5’-nucleotidases are known to play a critical role in B and T cell interactions. Spatial analyses between these cell types are ongoing.

Conclusions We report for the first time an enrichment of DN cells in breast cancer tumour tissue, specifically the expansion of DN2 cells in post NACT residual tissue. Functional analyses of tumour-infiltrated B-cells suggest that mechanistically, B-cell subgroups may contribute to immune surveillance and point to an important role of purinergic signalling in early breast cancers. Our study highlights the requirement for further investigation into the role of DN B cells in the context of chemo/immunotherapy resistance in breast cancers.

Ethics Approval Samples were collected from breast cancer patients undergoing treatment at Guy’s and St Thomas’ Hospital, London, after written informed consent as part of a non-interventional clinical study (BTBC study: REC No: 13/LO/1248, IRAS ID 131133). This study has local research ethics committee approval and was conducted adhering to the principles of the Declaration of Helsinki.

This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.